Walter J. Storkus

Walter J. Storkus's AcademicInfluence.com Rankings

Walter J. Storkus

Biology

#13184

World Rank

#16716

Historical Rank

Immunology

#901

World Rank

#924

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Walter J. Storkus Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Walter J. Storkus's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity (1995) (1168)
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines (1996) (913)
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity (1996) (790)
alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. (2004) (490)
NK susceptibility varies inversely with target cell class I HLA antigen expression. (1987) (467)
Tumor-Derived Microvesicles Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes1 (2009) (451)
Dendritic Cells Mediate NK Cell Help for Th1 and CTL Responses: Two-Signal Requirement for the Induction of NK Cell Helper Function 1 (2003) (389)
Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy (2002) (323)
Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. (1996) (296)
Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines (1996) (283)
Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB1*0401+ Patients With Renal Cell Carcinoma or Melanoma (2002) (272)
Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. (1993) (247)
Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. (1989) (246)
FLT3 ligand induces the generation of functionally active dendritic cells in mice. (1997) (219)
Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes (1995) (218)
Immunopolarization of CD4+ and CD8+ T Cells to Type-1–Like is Associated with Melanocyte Loss in Human Vitiligo (2003) (209)
Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. (1998) (209)
Complementary Dendritic Cell–activating Function of CD8+ and CD4+ T Cells (2002) (173)
Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models (2007) (171)
Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin (1996) (170)
Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. (2000) (165)
Bone Marrow‐Derived Dendritic Cells Serve as Potent Adjuvants for Peptide‐Based Antitumor Vaccines (1997) (162)
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics (2019) (151)
Melan-A/MART-151–73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells (2000) (151)
Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. (2003) (150)
Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. (2002) (145)
EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. (2005) (144)
Interleukin‐12 and B7.1 co‐stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors (1996) (140)
Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. (1993) (140)
Sunitinib facilitates the activation and recruitment of therapeutic anti‐tumor immunity in concert with specific vaccination (2011) (140)
Target structures involved in natural killing (NK): characteristics, distribution, and candidate molecules. (1991) (138)
Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. (2003) (136)
Genetically modified bone marrow‐derived dendritic cells expressing tumor‐associated viral or “self” antigens induce antitumor immunity in vivo (1997) (134)
Class I-induced resistance to natural killing: identification of nonpermissive residues in HLA-A2. (1991) (133)
NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. (2000) (132)
Innate Direct Anticancer Effector Function of Human Immature Dendritic Cells. II. Role of TNF, Lymphotoxin-α1β2, Fas Ligand, and TNF-Related Apoptosis-Inducing Ligand1 (2002) (127)
Helper role of NK cells during the induction of anticancer responses by dendritic cells. (2005) (119)
Soluble Fcgamma receptor type III (FcgammaRIII, CD16) triggers cell activation through interaction with complement receptors. (1996) (116)
Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells. (1999) (113)
DNA immunization targeting the skin: molecular control of adaptive immunity. (1998) (112)
New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines (1996) (112)
Innate Direct Anticancer Effector Function of Human Immature Dendritic Cells. I. Involvement of an Apoptosis-Inducing Pathway1 (2002) (110)
Identification of a Novel HLA-A*0201-restricted, Cytotoxic T Lymphocyte Epitope in a Human Glioma-associated Antigen, Interleukin 13 Receptor α2 Chain (2002) (110)
Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. (1993) (106)
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. (2000) (101)
Evaluation of the Modified ELISPOT Assay for Gamma Interferon Production in Cancer Patients Receiving Antitumor Vaccines (2000) (101)
Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. (2005) (98)
Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. (1999) (98)
Dendritic Cells Transduced with an Adenovirus Vector Encoding Epstein-Barr Virus Latent Membrane Protein 2B: a New Modality for Vaccination (1999) (94)
Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. (1996) (94)
IL‐12‐Engineered Dendritic Cells Serve as Effective Tumor Vaccine Adjuvants in Vivo a (1996) (93)
Polarized Type-1 Dendritic Cells (DC1) Producing High Levels of IL-12 Family Members Rescue Patient TH1-type Antimelanoma CD4+ T cell Responses In Vitro (2007) (91)
The alpha 1/alpha 2 domains of class I HLA molecules confer resistance to natural killing. (1989) (89)
Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. (2006) (89)
Gene-based strategies for the immunotherapy of cancer (1997) (85)
Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. (1994) (85)
Cytokine Gene Therapy of Cancer Using Interleukin‐12: Murine and Clinical Trials (1996) (84)
Direct transfection and activation of human cutaneous dendritic cells (2001) (83)
Identification of wild‐type and mutant p53 peptides binding to HLA‐A2 assessed by a peptide loading‐deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay (1994) (82)
Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice (1999) (79)
Effect of Renal Cell Carcinomas on the Development of Type 1 T-Cell Responses (2004) (78)
STING Agonists as Cancer Therapeutics (2021) (78)
IL-36γ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses. (2015) (77)
Dendritic Cell/Peptide Cancer Vaccines: Clinical Responsiveness and Epitope Spreading (2000) (72)
Patients With Renal Cell Carcinoma or Melanoma (2002) (72)
Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives (2017) (70)
MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. (2003) (70)
Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody (1990) (70)
Peptide-induced modulation of target cell sensitivity to natural killing. (1992) (68)
Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. (1999) (66)
Ectopic Expression of Interferon Regulatory Factor-1 Promotes Human Breast Cancer Cell Death and Results in Reduced Expression of Survivin (2004) (65)
Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. (2002) (64)
Interleukin‐7 (IL‐7) in Colorectal Cancer: IL‐7 is Produced by Tissues from Colorectal Cancer and Promotes Preferential Expansion of Tumour Infiltrating Lymphocytes (1997) (62)
Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. (2007) (62)
Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. (2006) (62)
Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors (2004) (61)
Delivery of Dendritic Cells Engineered to Secrete IFN-α into Central Nervous System Tumors Enhances the Efficacy of Peripheral Tumor Cell Vaccines: Dependence on Apoptotic Pathways1 (2005) (58)
Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy. (2002) (58)
Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? (2003) (57)
HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines. (1999) (56)
Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer Antigen Processing and Presentation Autologous Human Dendriphages Pulsed with Synthetic or Natural Tumor Peptides Elicit Tumor‐Specific CTLs In Vitro (1998) (56)
Tumor-Derived Vascular Pericytes Anergize Th Cells (2013) (56)
Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model (2012) (55)
Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation. (2005) (55)
Chronic inflammation and immunologic-based constraints in malignant disease. (2011) (54)
Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2‐derived peptide‐pulsed dendritic cell vaccines (2007) (53)
A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. (2010) (52)
gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells (2001) (52)
Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12. (2013) (51)
Proinflammatory Cytokines and CD40 Ligand Enhance Cross-Presentation and Cross-Priming Capability of Human Dendritic Cells Internalizing Apoptotic Cancer Cells (2001) (50)
Interferon-alpha (IFN-α)–conditioned DC Preferentially Stimulate Type-1 and Limit Treg-type In Vitro T-cell Responses From RCC Patients (2008) (49)
Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity (2007) (48)
Tbet and IL-36γ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment (2017) (47)
Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells. (2012) (47)
Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. (2011) (47)
Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer (2018) (47)
Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. (2019) (46)
Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma (2018) (45)
Delivery of Interferon-α Transfected Dendritic Cells into Central Nervous System Tumors Enhances the Antitumor Efficacy of Peripheral Peptide-Based Vaccines (2004) (45)
Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. (2002) (44)
Vaccines Targeting Tumor Blood Vessel Antigens Promote CD8+ T Cell-Dependent Tumor Eradication or Dormancy in HLA-A2 Transgenic Mice (2012) (44)
Killer dendritic cells: mechanisms of action and therapeutic implications for cancer (2008) (43)
Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity (2009) (41)
Modification of the Amino Terminus of a Class II Epitope Confers Resistance to Degradation by CD13 on Dendritic Cells and Enhances Presentation to T Cells1 (2000) (40)
Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma (2014) (40)
Myeloid-derived Suppressor Cells Adhere to Physiologic STAT3- vs STAT5-dependent Hematopoietic Programming, Establishing Diverse Tumor-Mediated Mechanisms of Immunologic Escape (2012) (39)
B cell sensitivity to natural killing: correlation with target cell stage of differentiation and state of activation. (1986) (39)
Murine Models of Cancer Cytokine Gene Therapy Using Interleukin‐12 a (1996) (39)
Ectopic T-bet Expression Licenses Dendritic Cells for IL-12-Independent Priming of Type 1 T Cells In Vitro1 (2009) (39)
Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine. (2009) (38)
Dendritic Cell Based Therapy of Cancer (1997) (38)
Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes. (1994) (38)
EBV‐Specific CD8+ T Cell Reactivation in Transplant Patients Results in Expansion of CD8+ Type‐1 Regulatory T Cells (2007) (38)
Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment. (2015) (37)
Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. (2007) (36)
Differential regulation of maturation and apoptosis of human monocyte-derived dendritic cells mediated by MHC class II. (2002) (36)
Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy. (2006) (36)
IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro (2006) (36)
Stat6 Signaling Suppresses VLA-4 Expression by CD8+ T Cells and Limits Their Ability to Infiltrate Tumor Lesions In Vivo1 (2008) (35)
IL-4-Transfected Tumor Cell Vaccines Activate Tumor-Infiltrating Dendritic Cells and Promote Type-1 Immunity1 (2005) (35)
Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells. (2009) (35)
CD8+ T-cell responses against hemoglobin-beta prevent solid tumor growth. (2008) (34)
Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy (2020) (34)
Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes. (1996) (33)
STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment (2021) (33)
miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction (2016) (33)
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy (2021) (32)
Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses. (2002) (32)
Disease-Stage Variance in Functional CD4+ T-Cell Responses Against Novel Pan-Human Leukocyte Antigen-D Region Presented Human Papillomavirus-16 E7 Epitopes (2004) (31)
IL-4 Suppresses Very Late Antigen-4 Expression Which is Required for Therapeutic Th1 T-cell Trafficking Into Tumors (2009) (31)
Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-β gene vector and dendritic cells (2003) (30)
EBV-specific memory CD8+ T cell phenotype and function in stable solid organ transplant patients. (2005) (30)
DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature. (2013) (30)
DC expressing transgene Foxp3 are regulatory APC (2010) (29)
Genetic Vaccines To Potentiate the Effective CD103+ Dendritic Cell–Mediated Cross-Priming of Antitumor Immunity (2015) (29)
EX VIVO GENERATION OF EFFECTIVE EPSTEIN-BARR VIRUS (EBV)-SPECIFIC CD8+ CYTOTOXIC T LYMPHOCYTES FROM THE PERIPHERAL BLOOD OF IMMUNOCOMPETENT EPSTEIN BARR VIRUS-SERONEGATIVE INDIVIDUALS1 (2000) (29)
Ex Vivo Priming of Naïve T Cells Into EBV‐Specific Th1/Tc1 Effector Cells by Mature Autologous DC Loaded with Apoptotic/Necrotic LCL (2003) (28)
Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes (1995) (28)
Enhancement in Specific CD8+ T Cell Recognition of EphA2+ Tumors In Vitro and In Vivo after Treatment with Ligand Agonists1 (2008) (27)
Human intestinal V delta 1+ T cells obtained from patients with colon cancer respond exclusively to SEB but not to SEA. (1995) (27)
JAK3/STAT5/6 Pathway Alterations Are Associated with Immune Deviation in CD8+ T Cells in Renal Cell Carcinoma Patients (2010) (27)
A Mycoplasma Peptide Elicits Heteroclitic CD4+ T Cell Responses against Tumor Antigen MAGE-A6 (2007) (26)
Tumor‐associated mesenchymal stem cells inhibit naïve T cell expansion by blocking cysteine export from dendritic cells (2016) (26)
Circulating Type-1 Anti-Tumor CD4+ T Cells are Preferentially Pro-Apoptotic in Cancer Patients (2014) (24)
IL‐4 inhibits VLA‐4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit (2008) (23)
A 'good death' for tumor immunology (2007) (23)
α-Type-1 Polarized Dendritic Cells (2004) (23)
Therapeutic Use of Dendritic Cells to Promote the Extranodal Priming of Anti-Tumor Immunity (2013) (23)
In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins. (2002) (22)
Quantitation and sorting of vitally stained natural killer cell-target cell conjugates by dual beam flow cytometry. (1986) (22)
Single injection of IL-12 coacervate as an effective therapy against B16-F10 melanoma in mice. (2019) (21)
IL-12 Production by Human Monocyte-Derived Dendritic Cells: Looking at the Single Cell (2005) (21)
Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells (2013) (21)
Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis. (1996) (20)
Molecular mimicry of MAGE-A6 and Mycoplasma penetrans HF-2 epitopes in the induction of antitumor CD8+ T-cell responses (2014) (19)
Dendritic cell-based vaccines and therapies for cancer (2002) (19)
Differentiation of Immunostimulatory Stem‐Cell‐ and Monocyte‐Derived Dendritic Cells Involves Maturation of Intracellular Compartments Responsible for Antigen Presentation and Secretion (2002) (19)
Therapeutic effectiveness of intratumorally-delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32 (2011) (18)
Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro. (2005) (18)
Intralesional Delivery of Dendritic Cells Engineered to Express T-bet Promotes Protective Type 1 Immunity and the Normalization of the Tumor Microenvironment (2010) (18)
Generation of robust CD8+ T‐cell responses against subdominant epitopes in conserved regions of HIV‐1 by repertoire mining with mimotopes (2010) (18)
Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8+ effector T cell responses (2016) (18)
TCR usage in CTLs recognizing melanoma/melanocyte antigens. (1995) (17)
Focus on FOCIS: interleukin 2 treatment associated autoimmunity. (2008) (17)
Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte. (1995) (17)
Translational Mini‐Review Series on Vaccines: Dendritic cell‐based vaccines in renal cancer (2007) (17)
Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells. (2001) (16)
TNF-Related Apoptosis-Inducing Ligand , Fas Ligand , and 2 β 1 α TNF , Lymphotoxin-Human Immature Dendritic Cells . II . Role of Innate Direct Anticancer Effector Function of Whiteside (2002) (16)
Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency (2014) (16)
The immunology of DNA vaccines. (2000) (15)
Identification of a Novel HLA-A * 0201-restricted , Cytotoxic T Lymphocyte Epitope in a Human Glioma-associated Antigen , Interleukin 13 Receptor 2 Chain 1 (2002) (15)
Integrating costimulatory agonists to optimize immune-based cancer therapies. (2009) (15)
Tumor-Derived α-Fetoprotein Directly Drives Human Natural Killer–Cell Activation and Subsequent Cell Death (2017) (15)
Categories of Tumor Antigens (2003) (14)
Dendritic cell based therapy of cancer. (1997) (14)
Biosynthesis and Functional Significance of Peripheral Node Addressin in Cancer-Associated TLO (2016) (14)
Augmentation of Type-1 Polarizing Ability of Monocyte-Derived Dendritic Cells from Chronically Immunosuppressed Organ-Transplant Recipients (2005) (13)
Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice (2017) (13)
Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells (2020) (13)
Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes. (2007) (13)
Immunotherapeutic Targeting of Tumor-Associated Blood Vessels. (2017) (12)
DNA vaccines targeting dendritic cells for the immunotherapy of cancer. (1998) (12)
Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist α-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity (2017) (12)
Oxygen‐Reactive Metabolites Are Not Detected at the Effector‐Target Interface During Natural Killing (1986) (12)
STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development (2021) (12)
Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines. (2016) (10)
NY-ESO-1 Encodes DRB 1 * 0401-restricted Epitopes Recognized by Melanoma-reactive CD 4 1 T Cells 1 (2000) (10)
Giving DNA vaccines a helping hand (1998) (10)
RGS5–TGFβ–Smad2/3 axis switches pro- to anti-apoptotic signaling in tumor-residing pericytes, assisting tumor growth (2021) (9)
Human Thymic Epithelial Cells Inhibit IL-15- and IL-2-Driven Differentiation of NK Cells from the Early Human Thymic Progenitors1 (2001) (9)
Class I-like CD1A-C do not protect target cells from NK-mediated cytolysis. (1996) (9)
Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma (2019) (9)
Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation (2006) (9)
Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo. (2012) (9)
T Lymphocytes + Apoptosis in Tumor-Reactive Activated CD 8 Regulatory T Cell Expansion and Induce Tumor-Derived Microvesicles Promote (2009) (8)
Activation of dendritic cells by surrogate T cell interactions leads to enhanced costimulation, secretion of TH1-associated cytokines, and CTL inductive capacity. (1997) (8)
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma (2021) (8)
Immunotherapy of melanoma: 9 (1993) (8)
Cancer-Testis (CT) Antigens (2003) (8)
Effective Tumor Immunotherapy Using Bone Marrow (bm)-derived Dendritic Cells (dcs) Genetically Engineered To Express Interleukin 12 (1997) (7)
IL-36 Signaling in the Tumor Microenvironment. (2020) (7)
Dysregulated NF-κB–Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma (2020) (7)
Immunologic Response to Renal Cell Carcinoma (2000) (7)
Progenipoietin‐generated dendritic cells exhibit anti‐tumor efficacy in a therapeutic murine tumor model (2002) (7)
Treatment-Enhanced CD4+Foxp3+ Glucocorticoid-Induced TNF Receptor Family RelatedHigh Regulatory Tumor-Infiltrating T Cells Limit the Effectiveness of Cytokine-Based Immunotherapy1 (2007) (7)
Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines (2009) (7)
Amino acid substitutions at position 97 in HLA‐A2 segregate cytolysis from cytokine release in MART‐1/Melan‐A peptide AAGIGILTV‐specific cytotoxic T lymphocytes (1996) (6)
Melan-A y MART-1 51–73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4 1 T cells (1999) (6)
Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation (2021) (6)
Use of autologous dendritic cells loaded with apoptotic LCL for ex vivo generation of specific CTL from the PBMC of EBV(-) individuals. (2001) (6)
Cytolytic T-cell clones define HLA-A2-restricted human cutaneous melanoma peptide epitopes: correlation with T-cell receptor usage. (1995) (6)
Melanoma antigens recognised by CD8+ and CD4+ T cells. (2000) (5)
Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium (2019) (5)
Tumor Arrests DN2 to DN3 Pro T Cell Transition and Promotes Its Conversion to Thymic Dendritic Cells by Reciprocally Regulating Notch1 and Ikaros Signaling (2020) (5)
Th 1-Biasing Cytokines Vitro by Blood-Derived Dendritic Cells and HIV-1-Specific CTL Responses Primed In Rinaldo (1999) (5)
Development of dendritic cell-based genetic vaccines for cancer. (1997) (5)
Shock block for improved immunotherapy (2012) (5)
Heat Shock Protein 90 Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin Enhances EphA 2 + Tumor Cell Recognition by Specific CD 8 + T Cells (2009) (5)
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary (2022) (4)
Update on vaccine development for renal cell cancer (2010) (4)
Sensory nerves impede the formation of tertiary lymphoid structures and development of protective anti-melanoma immune responses. (2022) (4)
CHAPTER 16 – Interleukin-12 Family [IL-12, 23, 12RA and 27] (2003) (4)
CD4+ T-Cell-Mediated Immunity to Cancer (2004) (3)
Enhancement in Specific CD 8 T Cell Recognition of EphA 2 Tumors In Vitro and In Vivo after Treatment with Ligand Agonists 1 (2008) (3)
Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines (2020) (3)
Vaccine therapy + dasatinib for the treatment of patients with stage IIIB-IV melanoma. (2016) (3)
PET Imaging of VLA-4 in a New BRAFV600E Mouse Model of Melanoma (2021) (2)
UPDATE ON VACCINE DEVELOPMENT FOR RENAL CELL CANCER. (2010) (2)
Adenovirus Inversely Modulates Target Cell Class I Antigen Expression and Sensitivity to Natural Killing (1989) (2)
Reactive Tc 1-type Immunity Local and Distant Disease in Association with Broadly Secrete Both Interleukin ( IL )-12 and IL-18 Effectively Treats Intratumoral Delivery of Dendritic Cells Engineered to Updated (2003) (2)
Monitoring antigen-specific T cell responses using real-time PCR. (2014) (2)
Combination Immunotherapy of Melanoma by inhibiting HSP90 and targeting its client proteins. (TUM7P.934) (2014) (2)
Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors (2021) (2)
Polarized DC1-Based Therapeutic Cancer Vaccines (2005) (2)
CHAPTER 59 – Cytokine gene transfer (2003) (1)
CANCER GENE THERAPY USING INTERLEUKIN-12 (IL-12) (1994) (1)
Dendritic cells (DCs) and the immunotherapy of melanoma: 012 (1997) (1)
Dendritic Cell Maturation Versus Polarization in Tumor Escape (2009) (1)
Immunotherapeutic targeting of HSP90 client proteins in BRAF-inhibitor resistant melanoma (2015) (1)
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males (2022) (1)
Dendritic Cells Mannose Receptor on Macrophages and Binding and Uptake of Agalactosyl IgG (1999) (1)
CD40 Cross-Linking Induces Migration of Renal Tumor Cell through Nuclear Factor of Activated T Cells (NFAT) Activation (2021) (1)
Can p53 peptides serve as tumor-specific antigens? (1993) (1)
MELANOMA IMMUNOGENICITY: MELANOMA CELLS PRESENT BOTH ENDOGENOUSLY—AND EXOGENOUSLY—DERIVED PEPTIDES TO CD8+ CYTOLYTIC T CELLS (1992) (1)
Melanoma vaccines: in search of a clinical paradigm. (2007) (1)
Generation of Anti-p 53 Cytotoxic T Lymphocytes from Human Peripheral Blood Using Autologous Dendritic Cells 1 (1999) (1)
INTERLEUKIN-10 INDUCES LYMPHOKINE-ACTIVATED KILLER (LAK) CELL ACTIVITY (1993) (1)
miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction (2016) (1)
Epithelial Tumor Antigens (2003) (1)
Integration of HSP90 inhibitors in combinational immunotherapy targeting receptor tyrosine kinases (RTKs) in cancer (131.45) (2010) (1)
Microenvironment and Immunology Combination Therapy with HSP 90 Inhibitor 17-DMAG Reconditions the Tumor Microenvironment to Improve Recruitment of Therapeutic T cells (2012) (1)
EVALUATION AND RESPONSE OF PATIENTS IMMUNIZED TO HLA-A2 POLYPEPITOPE PEPTIDE MIXTURE IN PATIENTS WITH METASTATIC MELANOMA USING AUTOLOGOUS DENDRITIC CELLS CULTURED WITH IL-4 AND GM-CSF (1997) (1)
EphA2: A Novel Target in Renal Cell Carcinoma (2009) (1)
Vascular Normalization, T Cell Trafficking and Anti-tumor Immunity (2016) (0)
Tumor blood vessel-associated antigens, DLK-1 and DLK-2, as targets for anti-cancer immunotherapy (2016) (0)
Therapeutic vaccination against tumor pericyte-associated antigens DLK1 and DLK2 (VAC12P.1013) (2014) (0)
Abstract OT1-01-02: Pilot trial of a type I polarized autologous dendritic cell vaccine incorporating tumor blood vessel antigen-derived peptides in patients with metastatic breast cancer (2016) (0)
STINGing the tumor microenvironment to promote therapeutic tertiary lymphoid organogenesis (2020) (0)
IMMUNOPOTENTIATION BY CD28 AND INTERLEUKIN-12 (1996) (0)
Abstract 1748: Head and neck cancer-derived exosomes facilitate carcinogenesis in the murine 4NQO chemically induced oropharyngeal cancer (2018) (0)
Engaging the Immune Response to Normalize the Tumor Microenvironment (2013) (0)
Combination Therapies to Improve Delivery of Protective T Cells into the Melanoma Microenvironment (2013) (0)
Pilot trial of a type I - polarized autologous dendritic cell vaccine incorporating tumor blood vessel antigen-derived peptides in patients with metastatic breast cancer (2015) (0)
Characterization of the immunophenotype of RCC patients who developed vitiligo-like depigmentation of the skin during the course of the spontaneous tumor regression (2007) (0)
New Avenues of Cancer Treatment: Modulation of Host Antitumor Directed Immune Responses by IL-4 and IL-12 in Renal Cell Cancer (1995) (0)
Transgenic Mice Tumor Eradication or Dormancy in HLA-A2 T Cell-Dependent + Antigens Promote CD8 Vaccines Targeting Tumor Blood Vessel (2012) (0)
Abstract 1537: Combined Tbet and IL-12 gene therapy elicits and recruits superior anti-tumor immunityin vivo (2012) (0)
CANCER GENE THERAPY USING IL-4, IL-12 OR IL-15 WITH THE COSTIMULATORY MOLECULES CD27, CD30, CD40 OR B7.1 (1995) (0)
Th1-Biasing Cytokines Vitro by Blood-Derived Dendritic Cells and HIV-1-Specific CTL Responses Primed In (1999) (0)
IL-36 g Transforms the Tum or Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses Graphical (2015) (0)
Abstract 1805: Integration of 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) in combinational immunotherapy targeting tumor antigen EphA2 (2011) (0)
Poorer survival outcomes in patients with multiple versus single primary melanoma (2022) (0)
Abstract 4399: Immunostimulatory effects of HSP90 inhibition: Insights from combinational immunotherapies targeting EphA2 (2012) (0)
Tumor-associatedmesenchymal stem cells inhibit naïve T cell expansion by blocking (2016) (0)
Expression and Immunogenicity of MAGE-3 and MAGE-6 in Squamous Cell Carcinoma of the Head and Neck (2004) (0)
In vitro generation of HLA-A2 restricted cytolytic T lympho-cytes using an HLA-A2+ allogeneic SCCHN cell line for lymphocyte stimulation (1999) (0)
Molecular Immunotherapeutics and Vaccines for Renal Cell Carcinoma and Its Vasculature (2013) (0)
Abstract 3824: Induction of potent antitumor immunity by intratumoral injection of mT-bet transduced dendritic cells (2010) (0)
87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known (2021) (0)
602 STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment (2020) (0)
The sialyl-glycolipid SSEA 4 marks a subpopulation of chemotherapy resistant breast cancer cells with mesenchymal features (2015) (0)
Abstract LB-225: Combination immunotherapy targeting HSP90 DNA-repair client proteins overexpressed in chemotherapy-resistant melanoma (2016) (0)
Dendritic engineered cells and uses for cancer treatment (2008) (0)
PD1 Blockade of Tumor-primed CD4 T Cells Instigates Protective Immunity Against Tumor Rechallenge. (2021) (0)
Infiltrate Tumor Lesions In Vivo T Cells and Limits Their Ability to + by CD8 Stat6 Signaling Suppresses VLA-4 Expression (2008) (0)
Novel mechanisms of anti-tumor action for therapeutic T-bet gene-modified dendritic cells (P4228) (2013) (0)
RTK-based vaccines elicit specific CD8+ T cell responses in HLA-A2 transgenic mice (48.1) (2007) (0)
Apoptotic Pathways Tumor Cell Vaccines: Dependence on Tumors Enhances the Efficacy of Peripheral into Central Nervous System a Secrete IFN-Delivery of Dendritic Cells Engineered to (2005) (0)
A NOVEL HLA-DR-RESTRICTED MELAN-A/MART-1 ANTIGEN REPRESENTS AN IMMUNOGENIC EPITOPE RECOGNIZED BY MELANOMA-SPECIFIC CD4+ T CELLS: IMPLICATIONS FOR VACCINE STRATEGIES (1999) (0)
IDENTIFICATION OF A CLASS I MHC-ASSOCIATED PEPTIDE DERIVED FROM THE METH A SARCOMA AND RECOGNIZED BY CD8+ T CELLS (1993) (0)
Immunotherapyof Cytokine-Based Tumor-Infiltrating T Cells Limit the Family RelatedHigh Regulatory Glucocorticoid-Induced TNF Receptor Treatment-Enhanced CD4+Foxp3+ (2013) (0)
Clinical features and survival outcomes in a prospective spontaneous regression (SR) protocol of renal cell carcinoma (RCC) and melanoma (M) patients. (2018) (0)
DC1-Based Protocols for Adoptive Immunotherapy for PTLD Boost Type-1 Anti-EBV CD8+ T Cell Responses in Solid Organ Tranplant Patients (2004) (0)
Enhances Presentation to T Cells Degradation by CD13 on Dendritic Cells and Class II Epitope Confers Resistance to Modification of the Amino Terminus of a (1999) (0)
Myeloid dendritic cell-specific mTORC2 deficiency enhances Th1 and Th17 cell responses and inhibits B16 melanoma growth (TUM6P.959) (2015) (0)
Transcriptomic profiling of peripheral blood mononuclear cells in patients with multiple primary melanoma. (2021) (0)
T lymphocyte responses effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ thaw cell lysates define an - Mature dendritic cells pulsed with freeze (2013) (0)
Neoepitopes as Difference Makers for General Cancer Vaccines? (2020) (0)
Abstract 4655: The prognostic significance of a 12-chemokine tertiary lymphoid structure (TLS) gene signature in uveal melanoma (UM) (2023) (0)
584 Therapeutic vascular normalization to promote tumor-associated tertiary lymphoid structures (2020) (0)
and Promote Type-1 Immunity Activate Tumor-Infiltrating Dendritic Cells IL-4-Transfected Tumor Cell Vaccines (2013) (0)
Conditional triggering of EphA2 epitope presentation results in the enhanced tumor cell recognition by specific CTL. (48.25) (2007) (0)
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males (2022) (0)
Idiotypes as Tumor Antigens (2003) (0)
88 Evidence of enhanced immune activation within the tumor microenvironment and the circulation of female patients with high-risk melanoma compared to males (2021) (0)
Immunotherapeutic targeting of HSP90 client proteins overexpressed in chemo-/radio-resistant melanoma (TUM2P.1012) (2015) (0)
Adjuvant administration of plasmid DNA expressing IL-12 enhances the induction of anti-melanoma immune responses with plasmid DNA encoding the murine melanosomal protein TRP-2 (1998) (0)
T cell repertoire sequencing reveals dynamics of response to dendritic cell vaccine plus dasatinib for checkpoint blockade resistant metastatic melanoma (2019) (0)
MicroRNAs in immune development/responses (WS-062) Chairpersons: Ken Ishii, Taro Fukao (2010) (0)
Modulation of tumor vasculature promotes tertiary lymphoid organogenesis. (2016) (0)
Cell Mediated Autophagy and Survival 2 (0)
Rescuing Anti-melanoma CD4+ Responses With Type-1 Polarized Dendritic Cells: Essential Roles of Extended IL-12 Family Members (2005) (0)
762 STING agonism combined with arginase, NOS2, and PTGES/COX2 inhibitors for improved anti-tumor immunotherapeutic benefit (2021) (0)
Abstract 3466: Tumor pericytes: A novel target for immune therapy in renal cell carcinoma (2011) (0)
Finding the right help in the tumor microenvironment (2022) (0)
Tumor pericyte-associated antigens DLK1 and DLK2 as targets for cancer immunotherapy (VAC13P.1131) (2015) (0)
Use of HSP90 inhibitors in the combination immunotherapy of melanoma (P4272) (2013) (0)
Cells from the Early Human Thymic IL-15- and IL-2-Driven Differentiation of NK Human Thymic Epithelial Cells Inhibit (2013) (0)
ENHANCED GENERATION OF HUMAN DENDRITIC CELLS FROM PERIPHERAL BLOOD MONONUCLEAR CELLS BY MONOCYTE DEPLETION WITH L-LEUCYL-L-LEUCINE METHYL ESTER (1995) (0)
MicroenvironmentNormalization of the Tumor Protective Type 1 Immunity and the Engineered to Express T-bet Promotes Intralesional Delivery of Dendritic Cells (2010) (0)
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy (2021) (0)
Vaccination against DLK-1 and DLK-2 as a cancer therapy (P4306) (2013) (0)
Efficient Ex Vivo Priming of Naïve Precursors into EBV-specific Type-1 CD8+ T Cell Responses from EBV Seronegative Pediatric HTx Patients Requires IL-12 and IL-27 (2007) (0)
Vitiligo and melanoma: in roads to immunotherapy (2004) (0)
Abstract 2683: Serum multiplex analysis of tertiary lymphoid structure-associated chemokines/cytokines in melanoma patients (2021) (0)
Intestinal V 81 + T Lymphocytes Recogn ize Tumor Cells o f Epithelial Origin (1996) (0)
Proliferation of vaccine draining lymph node lymphocytes (VDLNL) or IVS T Cells (IVS-T) in Culture with Bryostatin and Ionomycin (1997) (0)
STING agonism combined with arginase and PTGES/COX2 inhibitors for improved anti-tumor immunotherapeutic benefit (2021) (0)
Dasatinib is an effective adjuvant to therapeutic vaccination against melanoma (P4269) (2013) (0)
Abstract 5169: Sentinel lymph node gene expression signature predicts survival outcome in cutaneous melanoma (2022) (0)
Modulation of Immune Effector and Regulator Cells by Sunitinib: Potential for Combination Therapy in Renal Cell Carcinoma Patients (2012) (0)
Alpha-Type-1-Polarized DC (αDC1): DC-Based Vaccines with Optimized Anti-Cancer Activity (2004) (0)
Inhibition of HSPs for Enhanced Immunity (2018) (0)
Phase I-II vaccine trial with MHC class II and MHC class I epitopes from Melan-A/MART-1 for patients with metastatic melanoma. (2004) (0)
Abstract #5658: GITR and OX40 agonists initiate a biphasic Tcell response to mediate rejection of well-established tumors (2009) (0)
Cell Cycle Regulatory Proteins as Tumor Antigens (2003) (0)
Therapeutic Induction of Tertiary Lymphoid Structures in Melanoma using STING Agonists (2019) (0)
Gene Networks in the Developing Zebrafish Retina 8. Karis Kosar and Kari Nejak-Bowen. Determining the effects of Wnt signaling in the alleviation of cholestasis via the promotion of hepatocyte transdifferentiation (2020) (0)
IFN-Inducible Protein-10 Central Nervous System Tumor Response : Critical Roles of − Adoptive Transfer of Type 1 CTL Mediates Effective Anti (2006) (0)
More on cancer vaccine (2005) (0)
Combinational dasatinib and dendritic cell-based therapy improves therapeutic protection against melanoma growth (165.11) (2012) (0)
Combination immunotherapy integrating HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment for improved T cell recruitment and anti-tumor efficacy (52.19) (2012) (0)
Sentinel Lymph Node Gene Expression Signature Predicts Recurrence-Free Survival in Cutaneous Melanoma (2022) (0)
Promising targets in renal cell cancer: Met and ron-beta. (2006) (0)
Investigating the effects of nanoparticle phagocytosis on monocyte activation in diabetic hypertension 2 (2021) (0)
Thirty years of therapeutic innovation in melanoma research. (2021) (0)
HSP90 Inhibition Enhances the Anti-Tumor Efficacy of Combination Chemo Immunotherapy Targeting DNA Repair Proteins (2017) (0)
Helper Function Requirement for the Induction of NK Cell Th1 and CTL Responses: Two-Signal Dendritic Cells Mediate NK Cell Help for (2003) (0)
B 7 Cost imulat ion , and T Helper Cell 1-associated Cytokines (2003) (0)
TYPE-1 POLARIZATION OF CD8+ T CELL RESPONSES AGAINST EBV ANTIGENS IS PRESERVED IN IMMUNOSUPPRESSED STABLE SOLID ORGAN TRANSPLANT RECIPIENTS (2004) (0)
Abstract 5704: An integrated immune signature predictive of adjuvant immunotherapeutic benefits for high-risk melanoma (2023) (0)
IL-36γ promotes a local immune response via the formation of tertiary lymphoid structures in colorectal carcinoma. (2018) (0)
HSP90 inhibitor 17-DMAG enhances EphA2+ tumor cell recognition by specific CD8+ T cells (40.27) (2009) (0)
Application of Tumor Antigens for Clinical Immunotherapy (2003) (0)
PHASE I CLINICAL TRIAL OF INTERLEUKIN-12 (IL-12) CYTOKINE GENE THERAPY WITH OBJECTIVE RESPONSES IN CANCER PATIENTS WITH VARIOUS HISTOLOGIES (1997) (0)
THE NOVEL USE OF AUTOLOGOUS DENDRITIC CELLS LOADED WITH APOPTOTIC LCL FOR EX VIVO GENERATION OF SPECIFIC CTL FROM THE PBMC OF EBV INDIVIDUALS.: Abstract# 629 (2000) (0)
Dendritic cells transduced with T-bet and IL-12 effectively restrict immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in a murine tumor model (46.26) (2012) (0)
A NOVEL APPROACH TO GENERATE (EX VIVO) EBV-SPECIFIC CYTOTOXIC T CELLS FROM A NAÏVE IMMUNOCOMPETENT EBV-NEGATIVE INDIVIDUAL (1999) (0)
The α1/α2 Domains of Human Class I Molecules Confer Resistance to Natural Killing1 (1990) (0)
Dendritic cells engineered to secrete interleukin-12 p70 when delivered into tumors results in the crosspriming of an expanded anti-tumor CD8+ T cell repertoire and therapeutic benefit. (2007) (0)
Restoration of TH1 CD4+ T Cell Responses to Melanoma Antigens with Type-1 Polarized Dendritic Cells (2004) (0)
VIRAL IL-10 GENE TRANSDUCTION MARKEDLY INHIBITS THE ALLOSTIMULATORY ACTIVITY OF DENDRITIC CELLS. (1998) (0)
Dasatinib promotes an expanded and therapeutically-superior T cell repertoire in response to vaccination against melanoma (VAC12P.1014) (2014) (0)
IL-36 is required for the induction of therapeutic immunity by Tbet gene-modified dendritic cells. (TUM10P.1024) (2015) (0)
Editorial: Immunotherapy in renal cell carcinoma (2022) (0)
Genetically-modified dendritic cells serve as effective adjuvants in promoting antitumor immunity in vitro and in vivo (1996) (0)
Fas Ligand, and TNF-Related Apoptosis-Inducing Ligand (2002) (0)
Critical roles of IL-12/23 from tumor-infiltrating dendritic cells and Type-1 cytokine responses in the anti-tumor immunity induced by vaccination with interleukin-4 transfected tumors (2005) (0)
Vaccines in RCC: Clinical and Biological Relevance (2015) (0)
Abstract 2938: A novel OX40 agonist licenses systemic anti-tumor immunity to overcome local immune suppression induced by well-established tumors (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Walter J. Storkus?

Walter J. Storkus is affiliated with the following schools:

Walter J. Storkus's Academic­Influence.com Rankings

Why Is Walter J. Storkus Influential?

Walter J. Storkus's Published Works

Published Works

What Schools Are Affiliated With Walter J. Storkus?

Walter J. Storkus's AcademicInfluence.com Rankings